Protagonist Therapeutics, Inc. (PTGX)

Market Cap	2.42B
Revenue (ttm)	323.80M
Net Income (ttm)	170.85M
Shares Out	59.60M
EPS (ttm)	2.68
PE Ratio	15.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,047,619
Open	38.29
Previous Close	38.65
Day's Range	37.80 - 41.18
52-Week Range	16.80 - 48.89
Beta	2.16
Analysts	Strong Buy
Price Target	53.57 (+31.78%)
Earnings Date	Nov 7, 2024

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an oral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Financial Performance

In 2023, Protagonist Therapeutics's revenue was $60.00 million, an increase of 125.73% compared to the previous year's $26.58 million. Losses were -$78.96 million, -38.02% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $53.57, which is an increase of 31.78% from the latest price.

Price Target

$53.57

(31.78% upside)

Analyst Consensus: Strong Buy